<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1121" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1121/" /><meta name="ncbi_pagename" content="Hutchinson-Gilford Progeria Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Hutchinson-Gilford Progeria Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Hutchinson-Gilford Progeria Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/01/17" /><meta name="citation_author" content="Leslie B Gordon" /><meta name="citation_author" content="W Ted Brown" /><meta name="citation_author" content="Francis S Collins" /><meta name="citation_pmid" content="20301300" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1121/" /><meta name="citation_keywords" content="Hutchinson-Gilford Progeria Syndrome (HGPS), Classic" /><meta name="citation_keywords" content="Atypical Hutchinson-Gilford Progeria Syndrome" /><meta name="citation_keywords" content="Prelamin-A/C" /><meta name="citation_keywords" content="LMNA" /><meta name="citation_keywords" content="Hutchinson-Gilford Progeria Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Hutchinson-Gilford Progeria Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Leslie B Gordon" /><meta name="DC.Contributor" content="W Ted Brown" /><meta name="DC.Contributor" content="Francis S Collins" /><meta name="DC.Date" content="2019/01/17" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1121/" /><meta name="description" content="Hutchinson-Gilford progeria syndrome (HGPS) is characterized by clinical features that typically develop in childhood and resemble some features of accelerated aging. Children with HGPS usually appear normal at birth. Profound failure to thrive occurs during the first year. Characteristic facial features include head that is disproportionately large for the face, narrow nasal ridge, narrow nasal tip, thin vermilion of the upper and lower lips, small mouth, and retro- and micrognathia. Common features include loss of subcutaneous fat, delayed eruption and loss of primary teeth, abnormal skin with small outpouchings over the abdomen and upper thighs, alopecia, nail dystrophy, coxa valga, and progressive joint contractures. Later findings include low-frequency conductive hearing loss, dental crowding, and partial lack of secondary tooth eruption. Motor and mental development is normal. Death occurs as a result of complications of severe atherosclerosis, either cardiac disease (myocardial infarction or heart failure) or cerebrovascular disease (stroke), generally between ages six and 20 years. Average life span is approximately 14.5 years." /><meta name="og:title" content="Hutchinson-Gilford Progeria Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="Hutchinson-Gilford progeria syndrome (HGPS) is characterized by clinical features that typically develop in childhood and resemble some features of accelerated aging. Children with HGPS usually appear normal at birth. Profound failure to thrive occurs during the first year. Characteristic facial features include head that is disproportionately large for the face, narrow nasal ridge, narrow nasal tip, thin vermilion of the upper and lower lips, small mouth, and retro- and micrognathia. Common features include loss of subcutaneous fat, delayed eruption and loss of primary teeth, abnormal skin with small outpouchings over the abdomen and upper thighs, alopecia, nail dystrophy, coxa valga, and progressive joint contractures. Later findings include low-frequency conductive hearing loss, dental crowding, and partial lack of secondary tooth eruption. Motor and mental development is normal. Death occurs as a result of complications of severe atherosclerosis, either cardiac disease (myocardial infarction or heart failure) or cerebrovascular disease (stroke), generally between ages six and 20 years. Average life span is approximately 14.5 years." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1121/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/hgps/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1121/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B69E4E04246C100000000025B00CE.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1121_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1121_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/huppke-brendel/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sys-h/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1121_"><span class="title" itemprop="name">Hutchinson-Gilford Progeria Syndrome</span></h1><p class="contrib-group"><span itemprop="author">Leslie B Gordon</span>, MD, PhD, <span itemprop="author">W Ted Brown</span>, MD, PhD, and <span itemprop="author">Francis S Collins</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1121_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1121_ai__"><div class="contrib half_rhythm"><span itemprop="author">Leslie B Gordon</span>, MD, PhD<div class="affiliation small">Department of Pediatrics<br />Alpert Medical School of Brown University<br />Providence, Rhode Island<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.nworb@nodrog_eilsel" class="oemail">ude.nworb@nodrog_eilsel</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">W Ted Brown</span>, MD, PhD<div class="affiliation small">University of Sydney<br />Sydney, Australia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.loa@rbibtw" class="oemail">moc.loa@rbibtw</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Francis S Collins</span>, MD, PhD<div class="affiliation small">Director, National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.liam@fsnilloc" class="oemail">vog.hin.liam@fsnilloc</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">December 12, 2003</span>; Last Update: <span itemprop="dateModified">January 17, 2019</span>.</p><p><em>Estimated reading time: 24 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="hgps.Summary" itemprop="description"><h2 id="_hgps_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Hutchinson-Gilford progeria syndrome (HGPS) is characterized by clinical features that typically develop in childhood and resemble some features of accelerated aging. Children with HGPS usually appear normal at birth. Profound failure to thrive occurs during the first year. Characteristic facial features include head that is disproportionately large for the face, narrow nasal ridge, narrow nasal tip, thin vermilion of the upper and lower lips, small mouth, and retro- and micrognathia. Common features include loss of subcutaneous fat, delayed eruption and loss of primary teeth, abnormal skin with small outpouchings over the abdomen and upper thighs, alopecia, nail dystrophy, coxa valga, and progressive joint contractures. Later findings include low-frequency conductive hearing loss, dental crowding, and partial lack of secondary tooth eruption. Motor and mental development is normal. Death occurs as a result of complications of severe atherosclerosis, either cardiac disease (myocardial infarction or heart failure) or cerebrovascular disease (stroke), generally between ages six and 20 years. Average life span is approximately 14.5 years.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of classic or nonclassic <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> HGPS is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with characteristic clinical features, along with identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>LMNA</i> that results in production of the abnormal lamin A protein, progerin. Individuals with classic genotype HGPS are heterozygous for pathogenic variant <a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse">c.1824C&#x0003e;T</a> (~90% of individuals with HGPS). Individuals with nonclassic genotype HGPS have the characteristic clinical features of HGPS and are heterozygous for another <i>LMNA</i> pathogenic variant in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 or <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 11 that results in production of progerin (~10% of individuals with HGPS).</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> A regular diet with frequent small meals is recommended. Primary tooth extractions after the secondary tooth has erupted and/or fully descended may be required to avoid dental crowding. Use of sunscreen on all exposed areas of skin, including the head, is recommended for outdoor activities. Hip dislocation is best managed with physical therapy and body bracing; reconstructive hip surgery is possible, but comorbidities of surgery in this high-risk population should be considered. Shoe pads are recommended, as lack of body fat leads to foot discomfort. Routine physical and occupational therapy, active stretching and strengthening exercises, and hydrotherapy are recommended. Maintain optimal hydration, while encouraging physical activity, to minimize stroke risk. Anticoagulation as needed for cardiovascular and neurovascular complications. Medication dosages are based on body weight or body surface area, not age. Nitroglycerin can be beneficial for angina; anticongestive therapy is routine for the treatment of congestive heart failure. General anesthesia and intubation should be performed with extreme caution, ideally with fiberoptic intubation, if possible. Exposure keratopathy can be treated with ocular lubrication. Hearing aids can be used when clinically necessary. Age-appropriate schooling with adaptations for physical needs is usually recommended.</p><p><i>Prevention of secondary complications:</i> Low-dose aspirin (2-3 mg/kg body weight) is recommended for prevention of cardiovascular and stroke complications. Because the stiffened peripheral vasculature may be less tolerant to dehydration, maintaining optimal hydration orally is recommended.</p><p><i>Surveillance</i>: Annual or semiannual electrocardiogram (ECG), annual echocardiogram, carotid duplex ultrasound examination, neurologic examination, MRI/MRA of the head and neck, lipid profile, dental examination, hip x-ray to evaluate for avascular necrosis and progressing coxa valga, dual x-ray absorptiometry and/or peripheral cutaneous computed tomography to measure bone density, physical therapy assessment for joint contractures, ophthalmology examination, audiometry, and assessment of activities of daily living.</p><p><i>Agents/circumstances to avoid:</i> Dehydration; large crowds with taller/larger peers because of the risk of injury, trampolines and bouncy houses due to risk of hip dislocation. Physical activity should be self-limited.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Almost all individuals with HGPS have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Recurrence risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is small (as HGPS is typically caused by a <i>de novo</i> pathogenic variant) but greater than that of the general population because of the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Once the <i>LMNA</i> pathogenic variant has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk is possible.</p></div></div><div id="hgps.GeneReview_Scope"><h2 id="_hgps_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="hgps.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1121/table/hgps.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hgps.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hgps.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hutchinson-Gilford Progeria Syndrome: Included Genotypes</th></tr></thead><tbody><tr><td headers="hd_h_hgps.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Hutchinson-Gilford progeria syndrome (HGPS), classic</div></li><li class="half_rhythm"><div>Atypical Hutchinson-Gilford progeria syndrome</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#hgps.Nomenclature">Nomenclature</a>.</p></div></dd></dl></div></div></div></div><div id="hgps.Diagnosis"><h2 id="_hgps_Diagnosis_">Diagnosis</h2><div id="hgps.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Hutchinson-Gilford progeria syndrome (HGPS) <b>should be suspected</b> in individuals with severe growth failure, areas of sclerodermatous skin, partial alopecia that progresses to total alopecia by age two years, generalized lipodystrophy, retrognathia, x-ray findings including distal clavicular and terminal phalangeal resorption as well as coxa valga, and delayed/incomplete primary tooth eruption, all in the setting of normal intellectual development.</p><p><b>Growth deficiency</b></p><ul><li class="half_rhythm"><div>Short stature (&#x0003c;3rd percentile)</div></li><li class="half_rhythm"><div>Poor weight gain (&#x0003c;3rd percentile), weight distinctly low for height</div></li><li class="half_rhythm"><div>Diminished subcutaneous body fat globally</div></li></ul><p><b>Facial features</b> (see <a class="figpopup" href="/books/NBK1121/figure/hgps.F1/?report=objectonly" target="object" rid-figpopup="fighgpsF1" rid-ob="figobhgpsF1">Figure 1</a>)</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="fighgpsF1" co-legend-rid="figlgndhgpsF1"><a href="/books/NBK1121/figure/hgps.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="fighgpsF1" rid-ob="figobhgpsF1"><img class="small-thumb" src="/books/NBK1121/bin/hgps-Image001.gif" src-large="/books/NBK1121/bin/hgps-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndhgpsF1"><h4 id="hgps.F1"><a href="/books/NBK1121/figure/hgps.F1/?report=objectonly" target="object" rid-ob="figobhgpsF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Female age 11 years and male age six years with HGPS displaying classic features Photo courtesy of the Progeria Research Foundation</p></div></div><ul><li class="half_rhythm"><div>Head disproportionately large for face</div></li><li class="half_rhythm"><div>Long narrow nose</div></li><li class="half_rhythm"><div>Thin vermilion of the upper and lower lips</div></li><li class="half_rhythm"><div>Retrognathia and micrognathia</div></li></ul><p><b>Ectodermal</b></p><ul><li class="half_rhythm"><div>Dental. Delayed eruption and delayed loss of primary teeth, partial secondary tooth eruption, dental crowding</div></li><li class="half_rhythm"><div>Skin. Taut, variably pigmented, sclerodermatous, skin outpouchings over lower abdomen and/or proximal thighs</div></li><li class="half_rhythm"><div>Hair. Total alopecia, sometimes with very sparse downy immature hair remaining; loss of eyebrows</div></li><li class="half_rhythm"><div>Dystrophic nails</div></li></ul><p><b>Musculoskeletal</b></p><ul><li class="half_rhythm"><div>Coxa valga with wide-based, shuffling gait, sometimes accompanied by avascular necrosis of the femoral head</div></li><li class="half_rhythm"><div>Osteolysis of the distal phalanges</div></li><li class="half_rhythm"><div>Short clavicles with distal resorption</div></li><li class="half_rhythm"><div>Pear-shaped thorax</div></li></ul><p><b>Other</b></p><ul><li class="half_rhythm"><div>Thin, high-pitched voice</div></li><li class="half_rhythm"><div>Low-frequency conductive hearing loss</div></li><li class="half_rhythm"><div>Nocturnal lagophthalmos (the inability to fully close the eyes while sleeping)</div></li></ul></div><div id="hgps.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>Five major categories help to define <i>LMNA</i>-related disorders. Categories 1 and 2 define HGPS; categories 3-5 are not considered HGPS:</p><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin">Progerin-producing classic <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> HGPS</p></dd><dt>2.</dt><dd><p class="no_top_margin">Progerin-producing nonclassic <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> HGPS</p></dd><dt>3.</dt><dd><p class="no_top_margin">Non-progerin-producing progeroid laminopathies (see <a href="#hgps.Differential_Diagnosis">Differential Diagnosis</a>)</p><ul><li class="half_rhythm"><div>Due to <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>LMNA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that does not result in progerin production</div></li><li class="half_rhythm"><div>Due to pathogenic variants in other genes (e.g., <i>ZMPSTE24</i>)</div></li></ul></dd><dt>4.</dt><dd><p class="no_top_margin">Non-progeroid laminopathies (see <a href="#hgps.Differential_Diagnosis">Differential Diagnosis</a>)</p></dd><dt>5.</dt><dd><p class="no_top_margin">Non-laminopathy progeroid syndromes (see <a href="#hgps.Differential_Diagnosis">Differential Diagnosis</a>)</p></dd></dl><p>The diagnosis of <b>classic <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> HGPS is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the above <a href="#hgps.Suggestive_Findings">Suggestive Findings</a> and a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse">c.1824C&#x0003e;T</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>LMNA</i> identified on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1121/table/hgps.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="fighgpsTmoleculargenetictestingusedin" rid-ob="figobhgpsTmoleculargenetictestingusedin">Table 1</a>).</p><p>The diagnosis of <b>nonclassic <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> HGPS is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <a href="#hgps.Suggestive_Findings">Suggestive Findings</a> similar to classic genotype HGPS and an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> progerin-producing <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in either the <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 splice junction or <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 11 of <i>LMNA</i> identified on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1121/table/hgps.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="fighgpsTmoleculargenetictestingusedin" rid-ob="figobhgpsTmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>).</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Targeted analysis for <i>LMNA</i> pathogenic variants <a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse">c.1824C&#x0003e;T</a> (identified in 90% of individuals with HGPS), can be performed first in individuals with <a href="#hgps.Suggestive_Findings">Suggestive Findings</a> of HGPS.</div></li><li class="half_rhythm"><div class="half_rhythm">Sequence analysis of <i>LMNA</i> can be performed if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found on targeted analysis. Sequence analysis of <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 11 should be included if this was not already completed with targeted analysis.</div><div class="half_rhythm">Note: <i>LMNA</i> deletions and/or duplications have not been reported in individuals with HGPS.</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>LMNA</i>, <i>ZMPSTE24</i>, <i>a</i>nd other genes of interest (see <a href="#hgps.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>Comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing.</b> When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is indistinguishable from many other inherited disorders characterized by progeroid phenotype, comprehensive genomic testing (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="hgps.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Hutchinson-Gilford Progeria Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1121/table/hgps.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hgps.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hgps.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_hgps.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_hgps.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_hgps.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>LMNA</i></td><td headers="hd_h_hgps.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for classic <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> c.1824C&#x0003e;T</td><td headers="hd_h_hgps.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100% of classic <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> HGPS<br />~90% of all HGPS&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_hgps.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_hgps.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100% of all HGPS&#x000a0;<sup>3,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_hgps.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_hgps.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None identified</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hgps.TF.1.1"><p class="no_margin">See <a href="/books/NBK1121/#hgps.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="hgps.TF.1.2"><p class="no_margin">See <a href="#hgps.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="hgps.TF.1.3"><p class="no_margin">~90% of individuals with typical clinical features of HGPS will have the classic <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> (<a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse">c.1824C&#x0003e;T</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>). The remaining ~10% have heterozygous pathogenic variant <a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse">c.1822G&#x0003e;A</a> or a progerin-producing pathogenic variant in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 or <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 11 [<a class="bk_pop" href="#hgps.REF.gordon.2018b.1687">Gordon et al 2018b</a>].</p></div></dd><dt>4. </dt><dd><div id="hgps.TF.1.4"><p class="no_margin">Sequence analysis should include <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 11. Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="hgps.TF.1.5"><p class="no_margin">An individual with <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> has been identified using deep sequencing, whereby a child likely manifested two progerin-producing variants in different cells [<a class="bk_pop" href="#hgps.REF.bar.2017.212">Bar et al 2017</a>].</p></div></dd><dt>6. </dt><dd><div id="hgps.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd></dl></div></div></div></div></div><div id="hgps.Clinical_Characteristics"><h2 id="_hgps_Clinical_Characteristics_">Clinical Characteristics</h2><p>Individuals with <b>classic</b> and <b>nonclassic <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a></b>
<b>HGPS</b> have similar clinical features and spectrum of severity.</p><div id="hgps.Clinical_Description"><h3>Clinical Description</h3><p><b>Classic and nonclassic <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> Hutchinson-Gilford progeria syndrome (HGPS)</b> are characterized by clinical features that develop in childhood and resemble some features of accelerated aging. Children with progeria usually appear normal at birth and in early infancy.</p><p><b>Growth deficiency.</b> Profound failure to thrive usually occurs during the first year. Poor weight gain and loss of subcutaneous fat results in weight less than the third percentile for age, and weight that is distinctly low for height. Stature also decreases to below the third percentile for age.</p><p><b>Characteristic facial features</b> (see <a class="figpopup" href="/books/NBK1121/figure/hgps.F1/?report=objectonly" target="object" rid-figpopup="fighgpsF1" rid-ob="figobhgpsF1">Figure 1</a>) include a head that appears disproportionately large for face, narrow nasal ridge with a narrow nasal tip, thin vermilion of the upper and lower lips, small mouth, retrognathia, and micrognathia. Ogival (steeple-shaped) palatal vault occurs in 60%-70% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. A short, thick lingual frenulum that limits tongue mobility is seen in about 50% of affected individuals. Narrow airway and rigid laryngeal structures cause a high-pitched voice.</p><p><b>Dental.</b> Delayed eruption and delayed loss of primary teeth are common. Dental crowding occurs as a result of a small mouth, lack of primary tooth loss, and secondary tooth eruption behind the primary teeth. Secondary tooth eruption is often partial.</p><p><b>Skin.</b> Skin findings may be evident at birth and are present in all individuals by age two years. "Sclerodermatous" skin changes variably include areas that are described as taut, thickened, fibrotic, indurated, or rippled. In addition, dimpling or irregular small outpouchings can occur over the lower abdomen and proximal thighs. Skin also displays abnormal pigmentation consisting of light or dark macules and patches along with some papules and skin mottling.</p><p><b>Hair.</b> Partial alopecia progresses to total alopecia. Sparse downy hairs may be present on the occiput. Loss of eyebrows is common, and loss of eyelashes occurs in some individuals.</p><p><b>Nails.</b> Fingernails and toenails become dystrophic.</p><p><b>Musculoskeletal.</b> Individuals with HGPS are particularly susceptible to hip dislocation because of the progressive coxa valga malformation, which can be accompanied by avascular necrosis of the hip (osteonecrosis). Avascular necrosis can cause hip pain and is evident on x-ray. The coxa valga causes a wide-based shuffling gait. Additional bone changes include osteolysis of the distal phalanges, short clavicles with distal resorption, a pear-shaped thorax, and mildly low bone density for age. Fractures are not more commonly reported in individuals with HGPS. Extraskeletal calcifications are present in 40% of cases, with unknown clinical significance. Progressive stiffness of the joints due to tightened joint ligaments and osteoarthritis occurs with variable severity.</p><p><b>Endocrine.</b> Affected individuals do not become sexually mature. Females reach Tanner Stage 1 (78%) or 2 (22%) during pubertal years, and approximately 60% of females experience menarche [<a class="bk_pop" href="#hgps.REF.greer.2018.238">Greer et al 2018</a>]. No cases of fertility have been described. Serum leptin concentrations are below the limit of detection. Insulin resistance occurs in about 50% of individuals, without the overt development of diabetes mellitus.</p><p><b>Cardiovascular/cerebrovascular.</b> Individuals with HGPS develop severe atherosclerosis, usually without obvious abnormalities in lipid profiles [<a class="bk_pop" href="#hgps.REF.gordon.2005.336">Gordon et al 2005</a>]. In general, serum cholesterol, LDL, and triglyceride concentrations are not elevated and HDL concentrations may decrease with age. Diastolic dysfunction is an early cardiac abnormality, usually detected beyond age five years by tissue Doppler echocardiography [<a class="bk_pop" href="#hgps.REF.prakash.2018.326">Prakash et al 2018</a>]. Sequential manifestations of cardiovascular decline include impaired relaxation of the heart muscle, followed by ventricular hypertrophy. This may occur in the setting of heart valve thickening or stenosis, or with hypertension that is often labile. Mitral and aortic valve abnormalities, including calcification, stenosis, and regurgitation, usually develop in the second decade of life.</p><p>Systolic dysfunction is usually present in the setting of advanced disease, with or without identified coronary vascular insufficiency. Clinical symptoms of angina, dyspnea on exertion, or overt heart failure appear as late findings in the course of disease.</p><p>Transient ischemic attacks, silent strokes, or symptomatic strokes have occurred as early as age four years [<a class="bk_pop" href="#hgps.REF.silvera.2013.1091">Silvera et al 2013</a>]. Strokes can occur at any brain site and, therefore can lead to a variety of physical limitations and/or cognitive decline. Partial and complete carotid artery blockages can occur from plaque formation. Despite underlying vascular disease, most children do not have clinically identified strokes.</p><p>Raynaud phenomenon in fingers occurs in a minority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p>Death typically occurs as a result of complications of cardiac or cerebrovascular disease. More than 80% of deaths are due to heart failure and/or myocardial infarction, most often between ages six and 20 years, with an average life span of approximately 14.5 years [<a class="bk_pop" href="#hgps.REF.gordon.2014.27">Gordon et al 2014</a>, <a class="bk_pop" href="#hgps.REF.gordon.2018a.982">Gordon et al 2018a</a>].</p><p><b>Ophthalmologic.</b> Nocturnal lagophthalmos (the inability to fully close the eyes during sleep) is common. As a result, corneal dryness and clouding can occur. In a minority of individuals, corneal ulceration occurs due to exposure keratitis [<a class="bk_pop" href="#hgps.REF.mantagos.2017.126">Mantagos et al 2017</a>].</p><p><b>Hearing.</b> Conductive hearing loss is highly prevalent at all ages, with low-frequency hearing loss more prevalent than high-frequency [<a class="bk_pop" href="#hgps.REF.guardiani.2011.2250">Guardiani et al 2011</a>, <a class="bk_pop" href="#hgps.REF.gordon.2012.16666">Gordon et al 2012</a>].</p><p><b>Other</b></p><ul><li class="half_rhythm"><div>Motor and mental development are normal.</div></li><li class="half_rhythm"><div>Tumor rate is not increased over that of the general population. One individual died of a chondrosarcoma of the chest wall at age 13 years [<a class="bk_pop" href="#hgps.REF.king.1978.481">King et al 1978</a>].</div></li><li class="half_rhythm"><div>Other changes associated with normal aging such as nearsightedness or farsightedness, arcus senilis, senile personality changes, or Alzheimer disease have not been documented.</div></li><li class="half_rhythm"><div>Children with HGPS appear to have a normal immune system; they respond as well as the general population when subjected to various infections. Wound healing is normal.</div></li><li class="half_rhythm"><div>Liver, kidney, gastrointestinal, neurologic, and cognitive functions are normal.</div></li></ul></div><div id="hgps.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><div id="hgps.T.classic_genotype_hgps_and_nonclas" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Classic Genotype HGPS and Nonclassic Genotype HGPS: Causative <i>LMNA</i> Variants and Comparative Clinical Phenotypes</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1121/table/hgps.T.classic_genotype_hgps_and_nonclas/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hgps.T.classic_genotype_hgps_and_nonclas_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Genotype</th><th id="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LMNA</i> Pathogenic Variant (Predicted Protein Change)</th><th id="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotypic Features Compared to Classic HGPS&#x000a0;<sup>1</sup></th><th id="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"># of Affected Persons Identified</th><th id="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference</th></tr></thead><tbody><tr><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classic HGPS</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse">c.1824C&#x0003e;T</a><br />(p.Gly608=)&#x000a0;<sup>2</sup></td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 3</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">113</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#hgps.REF.eriksson.2003.293">Eriksson et al [2003]</a>, <a class="bk_pop" href="#hgps.REF.de_sandregiovannoli.2003.2055">De Sandre-Giovannoli et al [2003]</a></td></tr><tr><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_1" rowspan="9" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Nonclassic HGPS</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse"><u>c.1822G&#x0003e;A</u></a><br />(p.Gly608Ser)</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Moderate</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#hgps.REF.eriksson.2003.293">Eriksson et al [2003]</a>, PRF</td></tr><tr><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse">c.1821G&#x0003e;A</a><br />(p.Val607=)&#x000a0;<sup>2</sup></td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe; neonatal progeria</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#hgps.REF.moulson.2007.882">Moulson et al [2007]</a>, <a class="bk_pop" href="#hgps.REF.reunert.2012.933">Reunert et al [2012]</a>, PRF</td></tr><tr><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse">c.1968G&#x0003e;A</a><br />(p.Gln656=)&#x000a0;<sup>2</sup></td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Very mild</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#hgps.REF.hisama.2011.3002">Hisama et al [2011]</a>, <a class="bk_pop" href="#hgps.REF.barth_l_my.2015.1051">Barth&#x000e9;l&#x000e9;my et al [2015]</a></td></tr><tr><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse">c.1968+1G&#x0003e;C</a></td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#hgps.REF.iqbal.2008.266">Iqbal &#x00026; Iftikhar [2008]</a>, PRF</td></tr><tr><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse"><u>c.1968+1G&#x0003e;A</u></a></td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#hgps.REF.moulson.2007.882">Moulson et al [2007]</a>, <a class="bk_pop" href="#hgps.REF.navarro.2004.2493">Navarro et al [2004]</a>, PRF</td></tr><tr><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse"><u>c.1968+2T&#x0003e;A</u></a></td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#hgps.REF.bar.2017.212">Bar et al [2017]</a>, PRF</td></tr><tr><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse"><u>c.1968+2T&#x0003e;C</u></a></td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PRF</td></tr><tr><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse">c.1968+5G&#x0003e;A</a></td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Very mild</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#hgps.REF.hisama.2011.3002">Hisama et al [2011]</a>, PRF</td></tr><tr><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse"><u>c.1968+5G&#x0003e;C</u></a></td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Moderate</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3</td><td headers="hd_h_hgps.T.classic_genotype_hgps_and_nonclas_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PRF</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">HGPS = Hutchinson-Gilford progeria syndrome; PRF = Progeria Research Foundation Diagnostic Testing Program</p></div></dd><dt>1. </dt><dd><div id="hgps.TF.2.1"><p class="no_margin">There is a spectrum of severity for classic <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> HGPS, and most individuals with nonclassic genotype HGPS fall within that spectrum. Comparisons with classic genotype HGPS are based on the midrange of severity for classic genotype HGPS. Note that it is possible for a listed <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to yield a spectrum of disease severity among different <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div></dd><dt>2. </dt><dd><div id="hgps.TF.2.2"><p class="no_margin">= indicates that no effect on protein level is expected.</p></div></dd><dt>3. </dt><dd><div id="hgps.TF.2.3"><p class="no_margin">Individuals with <i>LMNA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse">c.1824C&#x0003e;T</a> appear remarkably similar in <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#hgps.REF.eriksson.2003.293">Eriksson et al 2003</a>].</p></div></dd></dl></div></div></div></div><div id="hgps.Penetrance"><h3>Penetrance</h3><p>Penetrance is complete.</p></div><div id="hgps.Nomenclature"><h3>Nomenclature</h3><p>HGPS is also referred to as the Hutchinson-Gilford syndrome or progeria.</p></div><div id="hgps.Prevalence"><h3>Prevalence</h3><p>The prevalence of children with HGPS per total population is one in 20 million [<a class="bk_pop" href="#hgps.REF.gordon.2014.27">Gordon et al 2014</a>].</p><p>The estimated birth incidence for HGPS is one in four million births with no observed differences based on ethnic background [<a class="bk_pop" href="#hgps.REF.hennekam.2006.2603">Hennekam 2006</a>].</p></div></div><div id="hgps.Genetically_Related_Allelic_Disorde"><h2 id="_hgps_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>Some 12 distinguishably different genetic conditions with nucleotide variants in <i>LMNA</i> have been identified. See OMIM <a href="http://omim.org/entry/150330" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">150330</a>. In addition, pathogenic variants in <i>ZMPSTE24</i>, which encodes zinc metalloproteinase, an enzyme involved in the post-translational processing of LMNA, can cause excess prelamin A proteins and a related <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (OMIM <a href="https://omim.org/entry/606480" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">606480</a>).</p><p><b>Non-progerin-producing progeroid laminopathy</b> can be used to describe phenotypes that overlap with classic and nonclassic <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> HGPS but are obviously different. Various pathogenic variants in <i>LMNA</i> identified through the <a href="https://www.progeriaresearch.org/the-prf-diagnostic-testing-program/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Progeria Research Foundation Diagnostic Testing Program</a>, <a href="https://www.progeriaresearch.org/international-progeria-registry/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">International Progeria Registry</a>, and/or <a href="https://www.progeriaresearch.org/medical-database/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Medical and Research Database Program</a> result in a variety of lamin A abnormalities that cause various phenotypes (see <a href="#hgps.Differential_Diagnosis">Differential Diagnosis</a>).</p><p><b>Non-progeroid laminopathies</b> caused by pathogenic <i>LMNA</i> variants that result in abnormal lamin A protein:</p><ul><li class="half_rhythm"><div>Autosomal dominant <a href="/books/n/gene/edmd/">Emery-Dreifuss muscular dystrophy</a> (AD-EDMD)</div></li><li class="half_rhythm"><div>Autosomal recessive <a href="/books/n/gene/edmd/">Emery-Dreifuss muscular dystrophy</a> (AR-EDMD)</div></li><li class="half_rhythm"><div>Autosomal dominant <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> dilated cardiomyopathy and conduction system defects (see <a href="/books/n/gene/dcm-ov/">Dilated Cardiomyopathy</a>)</div></li><li class="half_rhythm"><div>Autosomal dominant Dunnigan-type <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> partial lipodystrophy (FPLD) (OMIM <a href="https://omim.org/entry/151660" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">151660</a>)</div></li><li class="half_rhythm"><div>Autosomal dominant <a href="/books/n/gene/lgmd-overview/">limb-girdle muscular dystrophy</a> 1B (LGMD1B)</div></li><li class="half_rhythm"><div>Autosomal recessive axonal neuropathy Charcot-Marie-Tooth disease 2B1 (CMT2B1; see <a href="/books/n/gene/cmt/">Charcot-Marie-Tooth Hereditary Neuropathy Overview</a>)</div></li><li class="half_rhythm"><div>Autosomal recessive mandibuloacral dysplasia (MAD) [<a class="bk_pop" href="#hgps.REF.cao.2003.271">Cao &#x00026; Hegele 2003</a>]</div></li><li class="half_rhythm"><div>Single case reports of individuals with <i>LMNA</i> variants and unique clinical phenotypes [<a class="bk_pop" href="#hgps.REF.caux.2003.1006">Caux et al 2003</a>, <a class="bk_pop" href="#hgps.REF.kirschner.2005.148">Kirschner et al 2005</a>]</div></li></ul></div><div id="hgps.Differential_Diagnosis"><h2 id="_hgps_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Non-laminopathy progeroid syndromes.</b> Other syndromes that include some features of premature aging:</p><ul><li class="half_rhythm"><div>Neonatal progeroid syndrome (Wiedemann-Rautenstrauch syndrome) (OMIM <a href="http://omim.org/entry/264090" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">264090</a>)</div></li><li class="half_rhythm"><div>Acrogeria (OMIM <a href="http://omim.org/entry/201200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">201200</a>)</div></li><li class="half_rhythm"><div><a href="/books/n/gene/cockayne/">Cockayne syndrome</a></div></li><li class="half_rhythm"><div>Hallermann-Streiff syndrome (OMIM <a href="http://omim.org/entry/234100" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">234100</a>)</div></li><li class="half_rhythm"><div>Gerodermia osteodysplastica (OMIM <a href="http://omim.org/entry/231070" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">231070</a>)</div></li><li class="half_rhythm"><div><a href="/books/n/gene/bscl/">Berardinelli-Seip congenital lipodystrophy</a> (<a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> generalized lipodystrophy)</div></li><li class="half_rhythm"><div>Petty-Laxova-Weidemann progeroid syndrome (OMIM <a href="http://omim.org/entry/612289" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612289</a>)</div></li><li class="half_rhythm"><div>Ehlers-Danlos syndrome, progeroid form (OMIM <a href="http://omim.org/entry/130070" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">130070</a>)</div></li><li class="half_rhythm"><div><a href="/books/n/gene/werner/">Werner syndrome</a></div></li><li class="half_rhythm"><div>Mandibuloacral dysplasia (see <a href="#hgps.Genetically_Related_Allelic_Disorde">Genetically Related Disorders</a>) (OMIM <a href="http://omim.org/entry/248370" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">248370</a>)</div></li><li class="half_rhythm"><div>Nestor-Guillermo syndrome (OMIM <a href="http://omim.org/entry/614008" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">614008</a>)</div></li><li class="half_rhythm"><div>Penttinen Syndrome (OMIM <a href="https://omim.org/entry/601812" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">601812</a>)</div></li><li class="half_rhythm"><div><i>POLR3A</i>-related Wiedemann-Rautenstrauch syndrome (see <a href="/books/n/gene/pol3-leuk/">POLR3-Related Leukodystrophy</a>, <a class="bk_pop" href="#hgps.REF.wambach.2018.968">Wambach et al [2018]</a>)</div></li><li class="half_rhythm"><div><i>PYCR1</i>-related Wiedemann-Rautenstrauch-like syndrome [<a class="bk_pop" href="#hgps.REF.lessel.2018.921">Lessel et al 2018</a>]</div></li></ul></div><div id="hgps.Management"><h2 id="_hgps_Management_">Management</h2><div id="hgps.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with Hutchinson-Gilford progeria syndrome (HGPS), the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Weight and height plotted on standard growth charts to evaluate growth over time</div></li><li class="half_rhythm"><div>Electrocardiogram (ECG) and echocardiogram</div></li><li class="half_rhythm"><div>Carotid artery duplex scans to evaluate size of the lumen and intimal thickness in order to establish baseline vascular status</div></li><li class="half_rhythm"><div>MRI/MRA of the brain and neck</div></li><li class="half_rhythm"><div>Skeletal x-rays to evaluate for characteristic findings: acroosteolysis, clavicular resorption, coxa valga, and extraskeletal soft tissue calcifications [<a class="bk_pop" href="#hgps.REF.cleveland.2012.1089">Cleveland et al 2012</a>]</div></li><li class="half_rhythm"><div>Orthopedic evaluation for progressive coxa valga and/or avascular necrosis</div></li><li class="half_rhythm"><div>Dual-energy x-ray absorptiometry (DXA) to assess bone mineral density. Note: This must be normalized for height-age [<a class="bk_pop" href="#hgps.REF.gordon.2011.1670">Gordon et al 2011</a>].</div></li><li class="half_rhythm"><div>Occupational and physical therapy assessments, including six-minute walk test, goniometry to assess joint mobility, and assessment of activities of daily living</div></li><li class="half_rhythm"><div>Nutritional assessment, although dietary intake is generally not compromised in these patients</div></li><li class="half_rhythm"><div>Audiologic, ophthalmologic, and dental examinations</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="hgps.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>A complete, system-based management guide is available from the <a href="https://www.progeriaresearch.org/patient-care-and-handbook/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Progeria Research Foundation</a>.</p><p><b>Growth deficiency.</b> Frequent small meals tend to maximize caloric intake.</p><p><b>Dental.</b> Extraction of primary teeth may be required to avoid crowding and development of two rows of teeth. Since secondary teeth may erupt slowly or not at all, pulling primary teeth to make room for secondary teeth should be performed after secondary teeth have fully or almost fully erupted or almost fully descended. Once the primary tooth has been extracted, the secondary tooth often moves into the appropriate position with time.</p><p><b>Skin.</b> Use of sunscreen on all exposed areas of skin, including the head, is recommended for outdoor activities.</p><p><b>Orthopedic.</b> Conservative management of hip dislocation with physical therapy and body bracing when possible; surgical correction if essential, with special attention to intubation and anesthesia guidelines. Surgery should be treated as substantial risk for stroke and/or cardiac events. Podiatric evaluation is indicated to determine if shoe inserts are needed as lack of body fat leads to foot discomfort. Fracture rate is equivalent to the general pediatric population. When children do fracture, treatment and healing are routine.</p><p>Routine physical and occupational therapy is recommended to help maintain range of motion in large and small joints; see <a href="http://www.progeriaresearch.org/assets/files/pdf/Physical%20Therapy%2807-04%29.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Physical Therapy and Occupational Therapy in Progeria</a> (pdf). Active stretching and strengthening, along with hydrotherapy, are recommended.</p><p>In cases of dysfunctional vaginal bleeding or spotting, short-term (i.e., 3-6 months) provision of low-dose combined oral contraceptive pills can be helpful to stabilize the endometrium.</p><p><b>Cardiovascular.</b> A regular healthy diet is indicated unless the lipid profile becomes abnormal, at which point appropriate treatment includes exercise, diet modification, and medication as warranted. Avoiding anemia, dehydration, and high fever can be important, particularly in individuals with more advanced CV disease. Maintaining optimal hydration orally is recommended.</p><p>Prior to decline in cardiovascular or neurologic status (resulting from strokes, angina, or heart attacks), children should be encouraged to be physically active as tolerated, taking into account possible limitations related to restricted range of motion of joints and hip problems including osteoarthritis and hip dislocation.</p><p>Anticoagulants other than the routinely recommended aspirin (see <a href="#hgps.Prevention_of_Secondary_Complicatio">Prevention of Secondary Complications</a>) may be warranted if vascular blockage, transient ischemic attacks, stroke, angina, or myocardial infarction occur.</p><p>Although lipid profiles are usually normal, dietary therapy &#x000b1; statin therapy can be implemented if abnormalities occur.</p><p><b>Medications.</b> Dosages should be based on body weight or body surface area and not on age. Anesthetics should be used with particular caution.</p><ul><li class="half_rhythm"><div>Nitroglycerin is frequently of benefit if angina develops.</div></li><li class="half_rhythm"><div>Routine anticongestive therapy is appropriate if congestive heart failure is present.</div></li></ul><p><b>General anesthesia</b> and intubation should be performed with extreme caution, ideally with fiberoptic intubation. Individuals with HGPS have retrognathia, stiffened laryngeal structures, and a narrow and unusually shaped airway; additionally, they may exhibit an extreme sensitivity to alterations in blood pressure due to vascular stiffness.</p><p><b>Ophthalmologic.</b> Corneal dryness, clouding, or ulceration should be fully evaluated by an ophthalmologist. Exposure keratitis can be treated during daytime with ocular lubrication and during sleep with moisturizing ointment or by closing eyelids with skin tape.</p><p><b>Hearing loss.</b> Low-frequency conductive hearing loss often does not interfere with activities of daily living. Sitting at the front of the classroom can be helpful. Hearing aids can be used, when clinically necessary.</p><p><b>Education.</b> Because intellect and maturity are normal, age-appropriate schooling is usually indicated.</p><p><b>Infections</b> are generally handled as for unaffected children.</p></div><div id="hgps.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p><b>Aspirin.</b> Based on the evidence from adult studies that low doses of aspirin help delay heart attacks and strokes, it is probably appropriate to give children with HGPS low-dose aspirin treatment, at doses of 2-3 mg/kg body weight per day. Note: If chicken pox or influenza is prevalent in the community, it may be advisable to discontinue the aspirin during that time because of the increased risk of Reye syndrome.</p><p><b>Adequate oral hydration</b> is recommended, as the vasculature becomes generally less pliable and the risks of stroke and cardiac complications increase over time due to decreased vascular compensation. This is especially important during hot weather or airplane travel.</p><p><b>Vitamin supplementation.</b> Standard amounts of over-the-counter daily multivitamin tablets are appropriate. Calcium supplementation is not recommended, due to the potential for aggravating extraskeletal calcification formation and hypothetically aggravating vascular plaque status. Maintenance of normal calcium levels from dietary sources is encouraged.</p><p><b>Fluoride supplements</b> are recommended in areas where needed.</p><p><b>Immunizations.</b> The routine doses and administration schedule for all immunizations are recommended. Immunizations are generally handled as for unaffected children.</p></div><div id="hgps.Surveillance"><h3>Surveillance</h3><p>A complete, system-based management guide is available from the <a href="https://www.progeriaresearch.org/patient-care-and-handbook/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Progeria Research Foundation</a>.</p><p><b>Annually or semiannually.</b> Consistent measurement of blood pressure with the appropriately sized cuff, ECG, echocardiogram, and carotid duplex scans to monitor for cardiovascular disease. Note: Children may experience severe carotid artery atherosclerotic blockage prior to any significant ECG changes.</p><p><b>Annually</b></p><ul><li class="half_rhythm"><div>Neurologic assessment for signs and symptoms of headaches and stroke</div></li><li class="half_rhythm"><div>MRI/MRA of head and neck to assess for presence of vascular changes and silent strokes and to allow for the assessment of changes (increases) in risk over time</div></li><li class="half_rhythm"><div>Lipid profile</div></li><li class="half_rhythm"><div>Dental examination, x-ray, and cleaning</div></li><li class="half_rhythm"><div>Orthopedic evaluation for avascular necrosis (osteonecrosis) of the hip and progressing coxa valga that result in horse-riding stance and potential hip dislocation</div></li><li class="half_rhythm"><div>Occupational and physical therapy assessments including six-minute walk test, goniometry to assess joint mobility, and assessment of activities of daily living</div></li><li class="half_rhythm"><div>Ophthalmologic examination with special attention to possible exposure keratopathy</div></li><li class="half_rhythm"><div>Audiology evaluation with special attention to possible low-frequency conductive hearing loss</div></li></ul></div><div id="hgps.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Children should avoid being in the midst of large crowds with much taller and larger peers because of the increased risk of injury. Physical activity should be self-limited. Avoid uneven surfaces that could aggravate hip dysplasia, such as trampolines and bouncy houses. Avoid being carried by underage peers. Avoid dehydration due to increased risk of stroke.</p></div><div id="hgps.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#hgps.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="hgps.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search HGPS or progeria within <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical trials for HGPS.</p><p>The two therapies currently under human clinical trial investigation for HGPS are lonafarnib and everolimus (see <a class="figpopup" href="/books/NBK1121/figure/hgps.F2/?report=objectonly" target="object" rid-figpopup="fighgpsF2" rid-ob="figobhgpsF2">Figure 2</a>). Two clinical trials currently exist, with one administering <a href="https://www.clinicaltrials.gov/ct2/show/NCT00425607?term=lonafarnib&#x00026;cond=Hutchinson+Gilford+Syndrome&#x00026;rank=1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">lonafarnib monotherapy</a> and one administering <a href="https://www.clinicaltrials.gov/ct2/show/NCT02579044?cond=Progeria&#x00026;rank=2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">lonafarnib plus everolimus combination therapy</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="fighgpsF2" co-legend-rid="figlgndhgpsF2"><a href="/books/NBK1121/figure/hgps.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="fighgpsF2" rid-ob="figobhgpsF2"><img class="small-thumb" src="/books/NBK1121/bin/hgps-Image002.gif" src-large="/books/NBK1121/bin/hgps-Image002.jpg" alt="Figure 2. . Post-translational processing and medications currently under investigation in clinical treatment trials for HGPS." /></a><div class="icnblk_cntnt" id="figlgndhgpsF2"><h4 id="hgps.F2"><a href="/books/NBK1121/figure/hgps.F2/?report=objectonly" target="object" rid-ob="figobhgpsF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Post-translational processing and medications currently under investigation in clinical treatment trials for HGPS. Items in green promote the pathways. Items in red inhibit the pathways. * denotes medications tested in clinical trials. Everolimus is a <a href="/books/NBK1121/figure/hgps.F2/?report=objectonly" target="object" rid-ob="figobhgpsF2">(more...)</a></p></div></div><ul><li class="half_rhythm"><div>Lonafarnib is an investigational farnesyltransferase inhibitor. For HGPS, its target action is inhibition of post-translational farnesylation of progerin, the active disease-causing protein in HGPS. Lonafarnib is an oral medication administered twice daily. Clinical trial results for lonafarnib have revealed improvement in the rate of weight gain, vascular distensibility as measured via pulse wave velocity and vascular echodensity, bone rigidity, neurosensory hearing [<a class="bk_pop" href="#hgps.REF.gordon.2012.16666">Gordon et al 2012</a>], headaches [<a class="bk_pop" href="#hgps.REF.ullrich.2013.427">Ullrich et al 2013</a>], and life span [<a class="bk_pop" href="#hgps.REF.gordon.2014.27">Gordon et al 2014</a>, <a class="bk_pop" href="#hgps.REF.gordon.2018b.1687">Gordon et al 2018b</a>].</div></li><li class="half_rhythm"><div>Everolimus is a rapalog (rapamycin-like drug) mTOR inhibitor that additionally increases cellular autophagy. It is an oral medication administered once daily. Everolimus is approved as a medication to treat non-HGPS conditions. Rapamycin improved cellular phenotypes in HGPS fibroblasts via increased autophagy [<a class="bk_pop" href="#hgps.REF.cao.2011.2833">Cao et al 2011</a>, <a class="bk_pop" href="#hgps.REF.cenni.2011.e36">Cenni et al 2011</a>] and extends life span in a lamin A-deficient mouse model. Clinical trial results are not yet known.</div></li></ul><p><b>Other</b></p><ul><li class="half_rhythm"><div>A clinical treatment trial administering lonafarnib in combination with pravastatin and zoledronate demonstrated evidence of increased bone mineral density but no other improvements over that of lonafarnib monotherapy [<a class="bk_pop" href="#hgps.REF.gordon.2016.114">Gordon et al 2016</a>].</div></li><li class="half_rhythm"><div>A clinical treatment trial administering <a href="https://www.clinicaltrials.gov/ct2/show/NCT00731016?cond=Progeria&#x00026;rank=6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">pravastatin and zoledronate as combination therapy</a> has been conducted.</div></li></ul><p>The following proposed treatments have not been tested in humans (see <a class="figpopup" href="/books/NBK1121/table/hgps.T.potential_treatments_tested_only/?report=objectonly" target="object" rid-figpopup="fighgpsTpotentialtreatmentstestedonly" rid-ob="figobhgpsTpotentialtreatmentstestedonly">Table 3</a>). For a comprehensive review of evidence for these potential treatments, see <a class="bk_pop" href="#hgps.REF.strandgren.2017.1279">Strandgren et al [2017]</a>.</p><div id="hgps.T.potential_treatments_tested_only" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Potential Treatments Tested Only In Vitro and/or in Murine Studies</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1121/table/hgps.T.potential_treatments_tested_only/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hgps.T.potential_treatments_tested_only_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment/Drug</th><th id="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pathway</th><th id="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Target</th></tr></thead><tbody><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All-trans retinoic acid</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Autophagy</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progerin turnover</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Antisense oligonucleotides</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Access of <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> machinery</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lamin C / prelamin A <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> &#x00026;/or abnormal <i>LMNA</i> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a></td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DOT1L inhibitors</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cell reprogramming</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DOT1L</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Isoprenylcysteine carboxyl methyltransferase (ICMT) knock-down = shICMT</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prelamin A processing</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ICMT</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene editing</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CRISPR/Cas9</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LMNA sequence</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">JH4</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progerin-lamin A/C binding</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progerin-lamin A/C binding</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Metformin</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Activation of AMPK</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hepatic gluco-neogenesis</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Methylene blue</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mitochondrial biogenesis</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mitochondria function</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MG132 (a proteasome inhibitor )</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Autophagy</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progerin turnover</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mono-aminopyrimidines</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prelamin A processing</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prelamin A farnesylation</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N-acetyl cystine</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Oxidative stress</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reactive oxygen species</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">caNRF2</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NRF2 reactivation</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NRF2</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OSKM induction</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Epigenetic remodeling</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Partial cellular reprogramming</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pyrophosphate</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Metabolism of extracellular pyrophosphate</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Calcium-phosphate deposition</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rapamycin &#x00026; analogs</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Autophagy</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progerin turnover</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Remodelin</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Microtubule</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NAT10</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Resveratrol</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SIRT1 activity</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SIRT1</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sodium salicylate</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NF-&#x003ba;B signaling</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NF-&#x003ba;B inhibition</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stem cell transplantation</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stem cell function</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tissue regeneration</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sulforaphane</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Autophagy</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progerin turnover</td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Telomerase</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Telomere length</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Telomeres&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vitamin D</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vitamin D receptor signaling</td><td headers="hd_h_hgps.T.potential_treatments_tested_only_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vitamin D receptor</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hgps.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#hgps.REF.li.2017.804">Li et al [2017]</a>, not included in <a class="bk_pop" href="#hgps.REF.strandgren.2017.1279">Strandgren et al [2017]</a></p></div></dd></dl></div></div></div></div></div><div id="hgps.Genetic_Counseling"><h2 id="_hgps_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="hgps.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Hutchinson-Gilford progeria syndrome (HGPS) is typically caused by a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="hgps.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Almost all individuals with HGPS have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Approximately 3% of currently living individuals with the classic HGPS <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> identified through the Progeria Research Foundation Diagnostics Program have HGPS as the result of apparent <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> (or somatic and germline) <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> in a parent [<a class="bk_pop" href="#hgps.REF.wuyts.2005.66">Wuyts et al 2005</a>].</div></li><li class="half_rhythm"><div>Parents of probands are not <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Because HGPS is typically caused by a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is small.</div></li><li class="half_rhythm"><div>Currently there are three non-twin sib cases of HGPS among a total of 113 classic cases identified (2%). The number of unaffected sibs among the 113 total cases is unknown. Thus, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> for subsequent pregnancies after one individual has been genetically diagnosed with HGPS is significantly higher than the one in four million incidence for the general population, though still low.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Individuals with classic and nonclassic HGPS are not known to reproduce.</p></div><div id="hgps.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Origin of <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> Though the number of families evaluated is small, one study identified 4/4 cases as paternal in origin [<a class="bk_pop" href="#hgps.REF.eriksson.2003.293">Eriksson et al 2003</a>]. The pathogenic variant was maternal in origin for the case of <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> reported by <a class="bk_pop" href="#hgps.REF.wuyts.2005.66">Wuyts et al [2005]</a>. A study of paternal age effect found that on average the father's age was significantly increased by about five years [<a class="bk_pop" href="#hgps.REF.brown.1985.375">Brown et al 1985</a>]. There is no increase in <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a>.</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="hgps.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>LMNA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk (because of the rare possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent) and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="hgps.Resources"><h2 id="_hgps_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=hutchinsongilfordprogeriasyndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hutchinson-Gilford progeria syndrome</a></div></li><li class="half_rhythm"><div><b>Progeria Research Foundation (PRF)</b></div><div>PO Box 3453</div><div>Peabody 01961-3453</div><div><b>Phone:</b> 978-535-2594</div><div><b>Fax:</b> 978-535-5849</div><div><b>Email:</b> info@progeriaresearch.org</div><div><a href="http://www.progeriaresearch.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.progeriaresearch.org</a></div></li><li class="half_rhythm"><div><b>The Progeria Handbook: A Guide for Families &#x00026; Health Care Providers of Children with Progeria </b></div><div><a href="http://www.progeriaresearch.org/patient_care.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">The Progeria Handbook</a></div></li><li class="half_rhythm"><div><b>Progeria Research Foundation Patient Registry</b></div><div>PO Box 3453 (for mail)</div><div>Peabody MA 01961-3453</div><div><b>Phone:</b> 978-535-2594</div><div><b>Fax:</b> 978-535-5849</div><div><b>Email:</b> info@progeriaresearch.org</div><div><a href="http://www.progeriaresearch.org/patient_registry.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hutchinson-Gilford Progeria International Registry</a></div></li></ul></div><div id="hgps.Molecular_Genetics"><h2 id="_hgps_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="hgps.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Hutchinson-Gilford Progeria Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1121/table/hgps.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hgps.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_hgps.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_hgps.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_hgps.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_hgps.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_hgps.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_hgps.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_hgps.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4000" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>LMNA</i></a></td><td headers="hd_b_hgps.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4000" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q22</a></td><td headers="hd_b_hgps.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P02545" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Prelamin-A<wbr style="display:inline-block"></wbr>​/C</a></td><td headers="hd_b_hgps.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.interfil.org/details.php?id=NM_170707" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Human Intermediate Filament Database LMNA (lamin C1)</a><br /><a href="http://www.interfil.org/details.php?id=NM_170707" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Human Intermediate Filament Database LMNA (lamin A)</a><br /><a href="http://www.interfil.org/details.php?id=NM_170707" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Human Intermediate Filament Database LMNA (lamin C2)</a><br /><a href="http://www.molgen.ua.ac.be/CMTMutations/Mutations/Contexts.cfm?ID=21" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IPN Mutations, LMNA</a><br /><a href="http://www.umd.be/LMNA/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">The UMD-LMNA mutations database</a><br /><a href="https://databases.lovd.nl/shared/genes/LMNA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LMNA homepage - Leiden Muscular Dystrophy pages</a></td><td headers="hd_b_hgps.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=LMNA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LMNA</a></td><td headers="hd_b_hgps.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=LMNA[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LMNA</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="hgps.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="hgps.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Hutchinson-Gilford Progeria Syndrome (<a href="/omim/150330,176670" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1121/table/hgps.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hgps.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/150330" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">150330</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LAMIN A/C; LMNA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/176670" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">176670</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS</td></tr></tbody></table></div></div><div id="hgps.Molecular_Basis_of_Disease"><h3>Molecular Basis of Disease</h3><p>For the <i>LMNA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> c.1824C&#x0003e;T, the C-to-T transition does not change the translated glycine amino acid but activates a cryptic <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a>, resulting in a transcript with a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of 150 base pairs in the 3' portion of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11. Translation followed by post-translational processing of this altered <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> produces a shortened abnormal prelamin A protein with a 50-amino acid deletion near its C-terminal end, henceforth called "progerin." The 50-amino acid deletion removes the recognition site that leads to proteolytic cleavage of the terminal 18 amino acids of prelamin A, along with the phosphorylation site(s) involved in the dissociation and reassociation of the nuclear membrane at each cell division.</p><p>A key component of disease in HGPS is the presumably persistent farnesylation of progerin, which renders it permanently intercalated into the inner nuclear membrane, where it can accumulate and exert progressively more damage to cells as they age. That the failure to remove the farnesyl group is at least in part responsible for the phenotypes observed in HGPS is strongly supported by studies on both cell and mouse models that have either been engineered to produce a nonfarnesylated progerin product or treated with a drug that inhibits farnesylation, rendering a nonfarnesylated progerin product.</p><p>Other <i>LMNA</i> variants that do not result in the production of progerin protein result in abnormal lamin A proteins with variable abnormalities in their structure and function (including interactions with the nuclear membrane lamin-associated proteins), all of which produce cellular and organism diseases with varying phenotypes that overlap with HGPS in some aspects.</p><p><b>Gene structure.</b> The <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> of <i>LMNA</i> spans approximately 24 kb and contains 12 exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1121/#hgps.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> See <a class="figpopup" href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="fighgpsTlmnapathogenicvariantsdiscusse" rid-ob="figobhgpsTlmnapathogenicvariantsdiscusse">Table 4</a>.</p><div id="hgps.T.lmna_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>LMNA</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1121/table/hgps.T.lmna_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hgps.T.lmna_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1821G&#x0003e;A&#x000a0;<sup>1</sup></td><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val607=&#x000a0;<sup>2</sup></td><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_3" rowspan="10" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nucleotide/153281093" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_170707<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/27436946" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_733821<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1822G&#x0003e;A</td><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly608Ser</td></tr><tr><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1824C&#x0003e;T&#x000a0;<sup>1</sup></td><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly608=&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1968G&#x0003e;A</td><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln656=&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1968+1G&#x0003e;A</td><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(Splice donor site variant)</td></tr><tr><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1968+1G&#x0003e;C</td><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(Splice donor site variant)</td></tr><tr><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1968+2T&#x0003e;A</td><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(Splice donor site variant)</td></tr><tr><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1968+2T&#x0003e;C</td><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(Splice donor site variant)</td></tr><tr><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1968+5G&#x0003e;C</td><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(Splice donor site variant)</td></tr><tr><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1968+5G&#x0003e;A</td><td headers="hd_h_hgps.T.lmna_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(Splice donor site variant)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="hgps.TF.4.1"><p class="no_margin">In-frame <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 cryptic <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> activation variant</p></div></dd><dt>2. </dt><dd><div id="hgps.TF.4.2"><p class="no_margin">= indicates that no effect on protein level is expected.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The nuclear lamina is a protein-containing layer attached to the inner nuclear membrane. In mammals, it is composed of a family of polypeptides, with the major components being the lamins A, B1, B2, and C, with molecular weights ranging from 60,000 to 78,000. Lamins A and C are formed by alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of the <i>LMNA</i>/<i>C</i> gene transcript. Splicing within <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 10 gives rise to lamin C, whereas transcription of all 12 exons gives rise to lamin A. Lamins B1 and B2 are encoded by separate genes, and there are no known progeroid pathogenic variants within lamins B1 and B2.</p><p>Lamin A is normally synthesized as a precursor molecule (prelamin A) and undergoes four major post-translational processing steps. First, because prelamin A contains a CAAX (cysteine / aliphatic / aliphatic / any amino acid) box at its carboxyl terminus, it is modified by farnesylation. Following farnesylation, cleavage of the last three amino acids, <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> of the C-terminus, and internal proteolytic cleavage occur. Removal of the last 15 coding amino acids along with the CAAX box and farnesyl group generates mature lamin A with 646 amino acids.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The HGPS-causing variants in codon 608 of <i>LMNA</i> lead to activation of a cryptic <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> within <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11, resulting in production of a prelamin A that lacks 50 amino acids near the C terminus [<a class="bk_pop" href="#hgps.REF.eriksson.2003.293">Eriksson et al 2003</a>]. The c.1824C&#x0003e;T <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and consequent abnormal <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> produces a prelamin A that still retains the CAAX box and is therefore farnesylated, but is missing the site for endoproteolytic cleavage of the final 16 amino acids along with the farnesyl moiety that normally occurs during the final step in post-translational processing. The resulting protein, named progerin, is shortened and farnesylated. Since the lipophilic farnesyl moiety is utilized to anchor prelamin (and hence progerin) into the inner nuclear membrane, the lack of farnesyl cleavage likely results in long-term progerin association with the inner nuclear membrane.</p></div></div><div id="hgps.References"><h2 id="_hgps_References_">References</h2><div id="hgps.Published_Guidelines__Consensus_Sta"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hgps.REF1">Progeria Research Foundation. The Progeria Handbook: A Guide for Families &#x00026; Health Care Providers of Children with Progeria. Includes genetic testing guidelines. Available <a href="http://www.progeriaresearch.org/assets/files/PRFhandbook_0410.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a> (pdf). Accessed 1-8-19.</div></li></ul></div><div id="hgps.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.bar.2017.212">Bar DZ, Arlt MF, Brazier JF, Norris WE, Campbell SE, Chines P, Larrieu D, Jackson SP, Collins FS, Glover TW, Gordon LB. A novel somatic mutation achieves partial rescue in a child with Hutchinson-Gilford progeria syndrome. <span><span class="ref-journal">J Med Genet. </span>2017;<span class="ref-vol">54</span>:212–6.</span> [<a href="/pmc/articles/PMC5384422/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5384422</span></a>] [<a href="/pubmed/27920058" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27920058</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.barth_l_my.2015.1051">Barth&#x000e9;l&#x000e9;my F, Navarro C, Fayek R, Da Silva N, Roll P, Sigaudy S, Oshima J, Bonne G, Papadopoulou-Legbelou K, Evangeliou AE, Spilioti M, Lemerrer M, Wevers RA, Morava E, Robaglia-Schlupp A, L&#x000e9;vy N, Bartoli M, De Sandre-Giovannoli A. Truncated prelamin A expression in HGPS-like patients: a transcriptional study. <span><span class="ref-journal">Eur J Hum Genet. </span>2015;<span class="ref-vol">23</span>:1051–61.</span> [<a href="/pmc/articles/PMC4795109/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4795109</span></a>] [<a href="/pubmed/25649378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25649378</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.brown.1985.375">Brown WT, Zebrower M, Kieras FJ. Progeria, a model disease for the study of accelerated aging. <span><span class="ref-journal">Basic Life Sci. </span>1985;<span class="ref-vol">35</span>:375–96.</span> [<a href="/pubmed/4062819" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4062819</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.cao.2003.271">Cao H, Hegele RA. LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090). <span><span class="ref-journal">J Hum Genet. </span>2003;<span class="ref-vol">48</span>:271–4.</span> [<a href="/pubmed/12768443" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12768443</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.cao.2011.2833">Cao K, Blair CD, Faddah DA, Kieckhaefer JE, Olive M, Erdos MR, Nabel EG, Collins FS. Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts. <span><span class="ref-journal">J Clin Invest. </span>2011;<span class="ref-vol">121</span>:2833–44.</span> [<a href="/pmc/articles/PMC3223819/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3223819</span></a>] [<a href="/pubmed/21670498" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21670498</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.caux.2003.1006">Caux F, Dubosclard E, Lascols O, Buendia B, Chazouilleres O, Cohen A, Courvalin JC, Laroche L, Capeau J, Vigouroux C, Christin-Maitre S. A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2003;<span class="ref-vol">88</span>:1006–13.</span> [<a href="/pubmed/12629077" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12629077</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.cenni.2011.e36">Cenni V, Capanni C, Columbaro M, Ortolani M, D'Apice MR, Novelli G, Fini M, Marmiroli S, Scarano E, Maraldi NM, Squarzoni S, Prencipe S, Lattanzi G. Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria. <span><span class="ref-journal">Eur J Histochem. </span>2011;<span class="ref-vol">55</span>:e36.</span> [<a href="/pmc/articles/PMC3284238/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3284238</span></a>] [<a href="/pubmed/22297442" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22297442</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.cleveland.2012.1089">Cleveland RH, Gordon LB, Kleinman ME, Miller DT, Gordon CM, Snyder BD, Nazarian A, Giobbie-Hurder A, Neuberg D, Kieran MW. A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome. <span><span class="ref-journal">Pediatr Radiol. </span>2012;<span class="ref-vol">42</span>:1089–98.</span> [<a href="/pmc/articles/PMC4220680/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4220680</span></a>] [<a href="/pubmed/22752073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22752073</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.de_sandregiovannoli.2003.2055">De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, L&#x000e9;vy N. Lamin A truncation in Hutchinson-Gilford progeria. <span><span class="ref-journal">Science. </span>2003;<span class="ref-vol">300</span>:2055.</span> [<a href="/pubmed/12702809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12702809</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.eriksson.2003.293">Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. <span><span class="ref-journal">Nature. </span>2003;<span class="ref-vol">423</span>:293–8.</span> [<a href="/pubmed/12714972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12714972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.gordon.2011.1670">Gordon CM, Gordon LB, Snyder BD, Nazarian A, Quinn N, Huh S, Giobbie-Hurder A, Neuberg D, Cleveland R, Kleinman M, Miller DT, Kieran MW. Hutchinson-Gilford progeria is a skeletal dysplasia. <span><span class="ref-journal">J Bone Miner Res. </span>2011;<span class="ref-vol">26</span>:1670–9.</span> [<a href="/pmc/articles/PMC5650062/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5650062</span></a>] [<a href="/pubmed/21445982" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21445982</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.gordon.2018a.982">Gordon LB, Campbell SE, Massaro JM, D'Agostino RB Sr, Kleinman ME, Kieran MW, Moses MA. Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib. <span><span class="ref-journal">Pediatr Res. </span>2018a;<span class="ref-vol">83</span>:982–92.</span> [<a href="/pubmed/29342131" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29342131</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.gordon.2005.336">Gordon LB, Harten IA, Patti ME, Lichtenstein AH. Reduced adiponectin and HDL cholesterol without elevated C-reactive protein: clues to the biology of premature atherosclerosis in Hutchinson-Gilford progeria syndrome. <span><span class="ref-journal">J Pediatr. </span>2005;<span class="ref-vol">146</span>:336–41.</span> [<a href="/pubmed/15756215" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15756215</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.gordon.2016.114">Gordon LB, Kleinman ME, Massaro J, D'Agostino RB Sr, Shappell H, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland RH, Nazarian A, Snyder BD, Ullrich NJ, Silvera VM, Liang MG, Quinn N, Miller DT, Huh SY, Dowton AA, Littlefield K, Greer MM, Kieran MW. Clinical trial of the protein farnesylation inhibitors lonafarnib, pravastatin, and zoledronic acid in children with Hutchinson-Gilford progeria syndrome. <span><span class="ref-journal">Circulation. </span>2016;<span class="ref-vol">134</span>:114–25.</span> [<a href="/pmc/articles/PMC4943677/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4943677</span></a>] [<a href="/pubmed/27400896" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27400896</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.gordon.2012.16666">Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland R, Snyder BD, Fligor B, Bishop WR, Statkevich P, Regen A, Sonis A, Riley S, Ploski C, Correia A, Quinn N, Ullrich NJ, Nazarian A, Liang MG, Huh SY, Schwartzman A, Kieran MW. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2012;<span class="ref-vol">109</span>:16666–71.</span> [<a href="/pmc/articles/PMC3478615/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3478615</span></a>] [<a href="/pubmed/23012407" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23012407</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.gordon.2014.27">Gordon LB, Massaro J, D'Agostino RB Sr, Campbell SE, Brazier J, Brown WT, Kleinman ME, Kieran MW, et al.  Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. <span><span class="ref-journal">Circulation. </span>2014;<span class="ref-vol">130</span>:27–34.</span> [<a href="/pmc/articles/PMC4082404/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4082404</span></a>] [<a href="/pubmed/24795390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24795390</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.gordon.2018b.1687">Gordon LB, Shappell H, Massaro J, D'Agostino RB Sr, Brazier J, Campbell SE, Kleinman ME, Kieran MW. Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford progeria syndrome. <span><span class="ref-journal">JAMA. </span>2018b;<span class="ref-vol">319</span>:1687–95.</span> [<a href="/pmc/articles/PMC5933395/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5933395</span></a>] [<a href="/pubmed/29710166" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29710166</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.greer.2018.238">Greer MM, Kleinman ME, Gordon LB, Massaro J, D'Agostino RB Sr, Baltrusaitis K, Kieran MW, Gordon CM. Gordon pubertal progression in adolescent females with progeria. <span><span class="ref-journal">J Pediatr Adolesc Gynecol. </span>2018;<span class="ref-vol">31</span>:238–41.</span> [<a href="/pmc/articles/PMC6671321/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6671321</span></a>] [<a href="/pubmed/29258958" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29258958</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.guardiani.2011.2250">Guardiani E, Zalewski C, Brewer C, Merideth M, Introne W, Smith AC, Gordon L, Gahl W, Kim HJ. Otologic and audiologic manifestations of Hutchinson-Gilford progeria syndrome. <span><span class="ref-journal">Laryngoscope. </span>2011;<span class="ref-vol">121</span>:2250–5.</span> [<a href="/pmc/articles/PMC3688450/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3688450</span></a>] [<a href="/pubmed/21898437" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21898437</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.hennekam.2006.2603">Hennekam RC. Hutchinson-Gilford progeria syndrome: review of the phenotype. <span><span class="ref-journal">Am J Med Genet A. </span>2006;<span class="ref-vol">140</span>:2603–24.</span> [<a href="/pubmed/16838330" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16838330</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.hisama.2011.3002">Hisama FM, Lessel D, Leistritz D, Friedrich K, McBride KL, Pastore MT, Gottesman GS, Saha B, Martin GM, Kubisch C, Oshima J. Coronary artery disease in a Werner syndrome-like form of progeria characterized by low levels of progerin, a splice variant of lamin A. <span><span class="ref-journal">Am J Med Genet A. </span>2011;<span class="ref-vol">155A</span>:3002–6.</span> [<a href="/pmc/articles/PMC4679285/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4679285</span></a>] [<a href="/pubmed/22065502" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22065502</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.iqbal.2008.266">Iqbal M, Iftikhar A. Progeria - first case report from Pakistan. <span><span class="ref-journal">Rawal Med J. </span>2008;<span class="ref-vol">33</span>:266–7.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.king.1978.481">King CR, Lemmer J, Campbell JR, Atkins AR. Osteosarcoma in a patient with Hutchinson-Gilford progeria. <span><span class="ref-journal">J Med Genet. </span>1978;<span class="ref-vol">15</span>:481–4.</span> [<a href="/pmc/articles/PMC1013767/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1013767</span></a>] [<a href="/pubmed/284134" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 284134</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.kirschner.2005.148">Kirschner J, Brune T, Wehnert M, Denecke J, Wasner C, Feuer A, Marquardt T, Ketelsen UP, Wieacker P, Bonnemann CG, Korinthenberg R. p. S143F mutation in lamin A/C: a new phenotype combining myopathy and progeria. <span><span class="ref-journal">Ann Neurol. </span>2005;<span class="ref-vol">57</span>:148–51.</span> [<a href="/pubmed/15622532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15622532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.lessel.2018.921">Lessel D, Ozel AB, Campbell SE, Saadi A, Arlt MF, McSweeney KM, et al.  Analyses of LMNA-negative juvenile progeroid cases confirms biallelic POLR3A mutations in Wiedemann-Rautenstrauch-like syndrome and expands the phenotypic spectrum of PYCR1 mutations. <span><span class="ref-journal">Hum Genet. </span>2018;<span class="ref-vol">137</span>:921–39.</span> [<a href="/pmc/articles/PMC6652186/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6652186</span></a>] [<a href="/pubmed/30450527" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30450527</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.li.2017.804">Li Y, Zhou G, Bruno IG, Cooke JP. Telomerase mRNA reverses senescence in progeria cells. <span><span class="ref-journal">J Am Coll Cardiol. </span>2017;<span class="ref-vol">70</span>:804–5.</span> [<a href="/pubmed/28774385" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28774385</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.mantagos.2017.126">Mantagos IS, Kleinman ME, Kieran MW, Gordon LB. Ophthalmologic features of progeria. <span><span class="ref-journal">Am J Ophthalmol. </span>2017;<span class="ref-vol">182</span>:126–32.</span> [<a href="/pubmed/28756152" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28756152</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.moulson.2007.882">Moulson CL, Fong LG, Gardner JM, Farber EA, Go G, Passariello A, Grange DK, Young SG, Miner JH. Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:882–9.</span> [<a href="/pubmed/17469202" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17469202</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.navarro.2004.2493">Navarro CL, De Sandre-Giovannoli A, Bernard R, Boccaccio I, Boyer A, Genevieve D, Hadj-Rabia S, Gaudy-Marqueste C, Smitt HS, Vabres P, Faivre L, Verloes A, Van Essen T, Flori E, Hennekam R, Beemer FA, Laurent N, Le Merrer M, Cau P, Levy N. Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. <span><span class="ref-journal">Hum Mol Genet. </span>2004;<span class="ref-vol">13</span>:2493–503.</span> [<a href="/pubmed/15317753" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15317753</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.prakash.2018.326">Prakash A, Gordon LB, Kleinman ME, Gurary EB, Massaro J, D'Agostino R Sr, Kieran MW, Gerhard-Herman M, Smoot L. Cardiac abnormalities in patients with Hutchinson-Gilford progeria syndrome. <span><span class="ref-journal">JAMA Cardiol. </span>2018;<span class="ref-vol">3</span>:326–34.</span> [<a href="/pmc/articles/PMC5875332/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5875332</span></a>] [<a href="/pubmed/29466530" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29466530</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.reunert.2012.933">Reunert J, Wentzell R, Walter M, Jakubiczka S, Zenker M, Brune T, Rust S, Marquardt T. Neonatal progeria: increased ratio of progerin to lamin A leads to progeria of the newborn. <span><span class="ref-journal">Eur J Hum Genet. </span>2012;<span class="ref-vol">20</span>:933–7.</span> [<a href="/pmc/articles/PMC3421121/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3421121</span></a>] [<a href="/pubmed/22419169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22419169</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.silvera.2013.1091">Silvera VM, Gordon LB, Orbach DB, Campbell SE, Machan JT, Ullrich NJ. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2013;<span class="ref-vol">34</span>:1091–7.</span> [<a href="/pubmed/23179651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23179651</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.strandgren.2017.1279">Strandgren C, Rev&#x000ea;chon G, Sola-Carvajal A, Eriksson M. Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome. <span><span class="ref-journal">Biochem Soc Trans. </span>2017;<span class="ref-vol">45</span>:1279–93.</span> [<a href="/pubmed/29127216" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29127216</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.ullrich.2013.427">Ullrich NJ, Kieran MW, Miller DT, Gordon LB, Cho YJ, Silvera VM, Giobbie-Hurder A, Neuberg D, Kleinman ME. Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. <span><span class="ref-journal">Neurology. </span>2013;<span class="ref-vol">81</span>:427–30.</span> [<a href="/pmc/articles/PMC3776537/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3776537</span></a>] [<a href="/pubmed/23897869" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23897869</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.wambach.2018.968">Wambach JA, Wegner DJ, Patni N, Kircher M, Willing MC, Baldridge D, Xing C, Agarwal AK, Vergano SAS, Patel C, Grange DK, Kenney A, Najaf T, Nickerson DA, Bamshad MJ, Cole FS, Garg A. Bi-allelic POLR3A loss-of-function variants cause autosomal-recessive Wiedemann&#x02013;Rautenstrauch syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>2018;<span class="ref-vol">103</span>:968–75.</span> [<a href="/pmc/articles/PMC6288318/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6288318</span></a>] [<a href="/pubmed/30414627" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30414627</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hgps.REF.wuyts.2005.66">Wuyts W, Biervliet M, Reyniers E, D'Apice MR, Novelli G, Storm K. Somatic and gonadal mosaicism in Hutchinson-Gilford progeria. <span><span class="ref-journal">Am J Med Genet A. </span>2005;<span class="ref-vol">135</span>:66–8.</span> [<a href="/pubmed/15793835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15793835</span></a>]</div></li></ul></div></div><div id="hgps.Chapter_Notes"><h2 id="_hgps_Chapter_Notes_">Chapter Notes</h2><div id="hgps.Author_Notes"><h3>Author Notes</h3><p>Dr Gordon is an investigator for progeria clinical treatment trials being conducted at Boston Children's Hospital. For more information please contact Dr Gordon at Leslie_Gordon@brown.edu.</p></div><div id="hgps.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>17 January 2019 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 January 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 January 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>10 August 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>30 July 2004 (cd) Revision: Prenatal Testing</div></li><li class="half_rhythm"><div>11 February 2004 (wtb) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> now available</div></li><li class="half_rhythm"><div>12 December 2003 (me) Review posted live</div></li><li class="half_rhythm"><div>31 July 2003 (wtb) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1121</span><span class="label">PMID: <a href="/pubmed/20301300" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301300</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/huppke-brendel/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sys-h/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1121&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1121/?report=reader">PubReader</a></li><li><a href="/books/NBK1121/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1121" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1121" style="display:none" title="Cite this Page"><div class="bk_tt">Gordon LB, Brown WT, Collins FS. Hutchinson-Gilford Progeria Syndrome. 2003 Dec 12 [Updated 2019 Jan 17]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1121/pdf/Bookshelf_NBK1121.pdf">PDF version of this page</a> (775K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#hgps.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#hgps.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#hgps.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#hgps.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#hgps.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#hgps.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#hgps.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#hgps.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#hgps.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#hgps.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#hgps.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#hgps.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4000[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">LMNA</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1476164" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1476164" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1476164" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1476164" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301472" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">COL1A1/2</i> Osteogenesis Imperfecta</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">COL1A1/2</i> Osteogenesis Imperfecta<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Steiner RD, Basel D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21251803" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[Three cases of Hutchinson-Gilford progeria syndrome].</a><span class="source">[Arch Pediatr. 2011]</span><div class="brieflinkpop offscreen_noflow">[Three cases of Hutchinson-Gilford progeria syndrome].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Doubaj Y, Lamzouri A, Elalaoui SC, Laarabi FZ, Sefiani A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Arch Pediatr. 2011 Feb; 18(2):156-9. Epub 2011 Jan 19.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301510" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Marfan Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Marfan Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dietz H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23969228" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.</a><span class="source">[J Proteomics. 2013]</span><div class="brieflinkpop offscreen_noflow">Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Rivera-Torres J, Acín-Perez R, Cabezas-Sánchez P, Osorio FG, Gonzalez-Gómez C, Megias D, Cámara C, López-Otín C, Enríquez JA, Luque-García JL, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Proteomics. 2013 Oct 8; 91:466-77. Epub 2013 Aug 20.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301578" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia A</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia A<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Konkle BA, Huston H, Nakaya Fletcher S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301300" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301300" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04299839a66ee2baa1480d">Hutchinson-Gilford Progeria Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Hutchinson-Gilford Progeria Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:31:36-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8B69E4E04246C100000000025B00CE&amp;ncbi_session=CE8B69E4E0429981_0603SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1121%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1121&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1121/&amp;ncbi_pagename=Hutchinson-Gilford Progeria Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B69E4E0429981_0603SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>